Disease relevance of suloctidil

• Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor with restorative effects in a wide variety of rodent and primate models of Parkinson disease, but penetration into brain tissue from either the blood or the cerebro-spinal fluid is limited [1].
• The cerebro vascular system is implicated in the pathogenesis of many diseases of the cerebral white matter, for example, stroke, microcerebrovascular disease, and multiple sclerosis (MS) [2].
• Cerebro-cardiovascular and renal diseases were the major causes of death in the diabetic patients; heart disease was the cause of death in 16.9%, cerebrovascular disease in 16.4% and renal disease in 11.9% [3].
• Studies of suloctidil in experimental thrombosis in baboons [4].
• The endpoints used were death and new or worsening coronary, cerebro-, and peripheral vascular disease and neuropathy [5].

Psychiatry related information on suloctidil

• Suloctidil is a new drug that is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders [6].
• Thus, the primary analysis included 38 events in the suloctidil group and 47 in the placebo group (p = 0.17) representing a risk reduction of 24% [7].
• Idebenone is a new cerebro-active drug, effective in dementia disorders, particularly indicated in primary degenerative dementias, i.e. Alzheimer's disease [8].
• Influence of the physical and psychological stress on the cerebro-spinal purinergic fibers in adult rat [9].
• Influence of cerebro-spinal fluid of picrotoxin kindled rats on seizure susceptibility and locomotor activity of recipients [10].

High impact information on suloctidil

• Clark et al. conclude from their analysis of volumetric brain proportions ("cerebro-types") that cerebellum size is invariant across mammalian taxonomic groups, the neocortex and cerebellum do not co-vary in size (in contradiction to ref. 1), and cerebrotype-based measures identify directional changes in brain architecture [11].
• Elevated blood pressure is an important risk factor for renal-, cerebro- and cardiovascular diseases [12].
• The gamma band (26-40 Hz) showed strongest modulation for cerebro-muscular coherence and was strongest for the isometric contraction conditions [13].
• This study specifically addresses the issues of (i) task-relatedness, (ii) hemispheric symmetry, and (iii) frequency specificity of the measures power, cerebro-muscular coherence, and cerebro-cerebral coherence in bilateral primary motor cortex and supplementary motor area (SMA) [13].
• Power, cerebro-musclar coherence, and cerebro-cerebral coherence between these areas were computed for four frequency bands in each condition and subjected to ANOVA [13].

Chemical compound and disease context of suloctidil

• Because of ontogenic influences on the pathophysiologic mechanisms of brain injury in the perinatal brain, and in particular, the incomplete development of adenosine receptor systems, we investigated the potential for adenosine to provide cerebro-protection in a well established newborn rat model of hypoxia-ischemia [14].
• L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase [15].
• BW 1003C87, 5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine ethane sulphonic acid, has been tested for its in vitro and in vivo effects on glutamate release in rat brain tissue, and for its cerebro-protective action in two rodent models of cerebral ischemia [16].
• To investigate the cerebro-protective effect of flunarizine i.v. in patients successfully resuscitated from ventricular fibrillation outside hospital, a double-blind, placebo-controlled randomized study was started in February 1988 in West-Berlin with all eight Mobile Intensive Care Units and ten major hospitals participating [17].
• These properties of carvedilol should be suitable for treating hypertension resulting in cerebro- and cardiovascular diseases [18].

Biological context of suloctidil

• Methods of diagnosis were myelogram, computerized axial tomography, cerebro spinal fluid, chemistry and cytologies [19].
• In the present paper, recent data on cerebro cerebellar interactions is reviewed, particularly focusing on cerebellar influences over the neurophysiology of primary motor and primary sensory cortices [20].
• Effect of suloctidil on Na+/K+ ATPase activity and on membrane fluidity in rat brain synaptosomes [21].
• The effects of different cerebro-protective agents on selected key enzymes of the energy metabolism of rat primary glial cultures and rat cerebral cortex were studied [22].
• The synthetic quisqualate analogue, (S)-homoquisqualate was examined for activity at the glutamate metabotropic receptor, in relation to its ability to stimulate phosphoinositide hydrolysis in rat pup cerebro-cortical slices [23].

Anatomical context of suloctidil

• These results imply that an intact cerebro-basal ganglia loop is essential for awareness of limb position and suggest a selective role of the basal ganglia but not the cerebellum in kinaesthesia [24].
• Effects of suloctidil on platelet survival time following cardiac valve replacement [25].
• Mortality, cerebro- or cardiovascular events, amputations, arterial occlusions or number of revascularization procedures performed in the lower limbs, pain-free and total walking distance, ankle brachial index and calf blood flow, were the main outcomes considered [26].
• The effects of small doses are attributed to a local action in the brainstem which causes inhibition of spinal neurones either by activating descending inhibitory neuronal systems or by liberating endogenous substances which reach the spinal cord via the cerebro-spinal fluid [27].
• This point kernel approach was used in combination with a distance histogram technique, to study in more detail the absorbed dose distribution in the cerebro-spinal fluid, in the surface of the central nervous system, and in tumor sites [28].

Associations of suloctidil with other chemical compounds

• The stimulatory effect of suloctidil on the release of the platelet inhibitor PGI2 from the vascular endothelium might contribute to the known antiplatelet and antithrombotic activity of this drug [29].
• Hypoglycorrhachia (abnormally low cerebro spinal fluid glucose content) eludes exact numerical definition, largely because of the dynamic equilibrium between blood and CSF glucose [30].
• Does adenosine have cerebro-protective effect during cardiopulmonary bypass [31]?
• The concentrations of unbound bilirubin in the cerebro-spinal fluid and CNS cells are probably limited mainly by active export of bilirubin back into plasma, mediated by ABC transporters present in the brain capillary endothelium and choroid plexus epithelium [32].
• In anorectic tumor-bearing rats, we detected upregulation of IL-1beta and IL-1 receptor mRNA levels in the hypothalamus, a negative correlation between IL-1 concentration in cerebro-spinal fluid and food intake and high levels of hypothalamic serotonin, and these differences disappeared after tumor removal [33].

Gene context of suloctidil

• The patients with this mutation did not have cerebro-muscular symptoms as were observed in MELAS [34].
• Previously we have reported serum amyloid P component (SAP) induced cell death in cerebro-cortical cultures of rat brain [35].
• The PMCA1 is the most abundant in the cerebro-cortical and hippocampal membrane preparations [36].
• These results suggest that selective 5-HT1D and 5-HT1F receptor agonists might represent new antimigraine drugs devoid of cerebro- and cardiovascular effects [37].
• Influence of thyroid hormones on somatostatin processing in cultured cerebro-cortical cells [38].

Analytical, diagnostic and therapeutic context of suloctidil

• Using a recently developed analysis tool (Dynamic Imaging of Coherent Sources; DICS), we determined cerebro-muscular and cerebro-cerebral coherence as well as the partial coherence between cerebral areas and muscle, and localized coherent sources within the individual MRI scans [39].
• The results after oral administration of suloctidil (100 mg/kg/d in two divided doses) were not different from control studies [4].
• Cannula platelet consumption was unaffected by suloctidil (20 mg/kg/d given in two divided doses for two days preceding and throughout the period of platelet survival measurement) [4].
• A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis [40].
• Cerebro-cortical laser-Doppler flow (cortical perfusion, CP), arterial blood pressure, core temperature, PaO2, PaCO2, pH and glycemia were measured before, during and after MCAO [41].

References